Company news
Assembly Biosciences, Inc. (NASDAQ:ASMB) news
Assembly Biosciences, Inc. news releases on 6ix. Latest, Feb 26, 2021: Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple…
Press releases — page 3
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
February 25, 2021
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
February 24, 2021
Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights
February 24, 2021
Assembly Bio Announces Upcoming Investor Events
February 18, 2021
Assembly Biosciences to Wind-Down Microbiome Program
December 7, 2020
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
November 16, 2020
Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators
November 15, 2020
Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update
November 4, 2020
Assembly Biosciences Appoints Gina Consylman to Board of Directors
October 19, 2020
Assembly Biosciences Announces October Conference Participation
October 4, 2020
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
August 26, 2020
Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
July 19, 2020
Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection
July 8, 2020
Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
June 24, 2020
Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs
June 17, 2020
Assembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 31, 2020
Assembly Biosciences Announces Management Transition
May 26, 2020
Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020
May 18, 2020
Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results
May 6, 2020
Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 30, 2020
Assembly Biosciences to Host Conference Call and Webcast to Review HBV Portfolio Progress
April 29, 2020
Assembly Biosciences Appoints Jason Okazaki as Chief Legal and Business Officer
March 29, 2020
Assembly Biosciences Reports Fourth Quarter and Year End 2019 Financial Results
March 3, 2020
Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 15, 2019
Assembly Biosciences Announces Pricing of $125 Million Public Offering
December 11, 2019
Assembly Biosciences Announces Proposed Public Offering of Common Stock
December 10, 2019
Assembly Biosciences Announces Plenary Lecture at HEP DART 2019
December 5, 2019
Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
November 6, 2019
Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer
November 6, 2019
Assembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer
October 27, 2019
Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
April 12, 2019